New Leaf Venture Partners
Venture Capital
Active
New York, United States
183
35M
93
9.63
27
0.49
47
- Stages of investment
- Areas of investment
Summary
New Leaf Venture Partners appeared to be the VC, which was created in 2005. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the New York.
The high activity for fund was in 2012. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. When the investment is from New Leaf Venture Partners the average startup value is more than 1 billion dollars. Comparing to the other companies, this New Leaf Venture Partners performs on 3 percentage points less the average number of lead investments. The top amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 7-12 deals per year.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the New Leaf Venture Partners, startups are often financed by Spray Venture Partners, InterWest Partners, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Aberdare Ventures, Clarus Ventures. In the next rounds fund is usually obtained by SV Health Investors, Aberdare Ventures, Three Arch Partners.
This organization was formed by James Niedel, Jeani Delagardelle, Philippe Chambon, Ronald M. Hunt, Vijay Lathi. The overall number of key employees were 2.
Among the most successful fund investment fields, there are Genetics, Health Diagnostics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Synageva BioPharma, Intarcia Therapeutics, Relypsa The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 200000000
- Fund raised date
- 2015-06-22
Analytics
- Total investments
- 183
- Lead investments
- 27
- Exits
- 47
- Rounds per year
- 9.63
- Follow on index
- 0.49
- Investments by industry
- Health Care (136)
- Biotechnology (121)
- Medical (61)
- Medical Device (54)
- Therapeutics (42) Show 46 more
- Investments by region
-
- United States (164)
- United Kingdom (7)
- Ireland (2)
- Denmark (1)
- Switzerland (1) Show 4 more
- Peak activity year
- 2012
- Number of Unicorns
- 5
- Number of Decacorns
- 5
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 210M
- Group Appearance index
- 0.97
- Avg. company exit year
- 8
- Avg. multiplicator
- 4.95
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ayez | 01 Jun 2018 | Seed | 0 | United States, California, Mountain View | |
| Qlaris Bio | 30 Apr 2024 | Biotechnology, Health Care, Medical | Early Stage Venture | 24M | United States, Massachusetts, Cambridge |
| UNUM Therapeutics | 11 Jun 2015 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 65M | United States, Massachusetts, Cambridge |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.